AlerGenetica has advanced the approach for treatment of fungal allergy conditions. Our therapeutics are based on small proteins. Small proteins can be easily chemically synthesized under pharmaceutical production and quality control conditions to insure composition and purity.

Our therapeutics do not contain recombinant DNA or other types of proteins as contaminants. Using specific tests, our small proteins can be assayed for biological activity in representative patient populations. 

For use in allergy immunotherapy treatments, small proteins can be manufactured that do not contain structures that react with IgE and thus have increased safety. This allows us to significantly shorten the treatment time and number of treatments needed.